Henlius Facts
  • 2010
    Founded in Shanghai
  • Stock Code
    2696.HK
  • First Launched
    Biosimilar in China
  • 20+
    Candidates in R&D
  • Global R&D Facilities
    Shanghai, Taipei and California
Comprehensive Platform
News
關于
複宏漢霖
生物技術
上海復宏漢霖生物技術股份有限公司由復星醫藥與海外科學家團隊于2010年2月合資組建,公司主要致力于符合全球標準的生物類似藥及創新型抗體藥物的研發和生產。
A Galaxy of Talents
A Galaxy of Talents
共謀發展

In Henlius, employees are our most important resources and most valuable assets. Talents are top on our priorities.

We value talents by retaining them, developing them and putting right people to right place.

福建快3基本走势一定牛